The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a greater substantial loss in body size and enhance metabolic function, part